Article Figures & Data
Figures
Tables
Data Supplement
- Supplemental Data -
Supplementary Figure 1 - Effect of pre-experimental period on mucosal-to-serosal transport of cefadroxil and methotrexate.
Supplementary Figure 2 - Effect of pre-experimental period on the mRNA expression levels of ABCB1, ABCG2, SLC15A1, SLC46A1, and GAPDH in human intestinal sections.
Supplementary Figure 3 - Effect of the pre-experimental period on the expression levels of P-gp, BCRP, and PEPT1 protein in human intestinal sections.
Supplementary Figure 4 - The apparent permeability coefficient (Papp) for the mucosalto-serosal or serosal-to-mucosal transport of lucifer yellow and propranolol across human intestinal sections originated from 16 independent subjects (#1–#16).
Supplementary Figure 5 - Effects of age and gender of the subjects on the apparent permeability coefficient (Papp) of lucifer yellow and propranolol across human intestinal sections originated from 16 independent subjects (#1–#16).
Supplementary Figure 6 - Correlation between the relative mRNA expression levels of transporters and the ratio of the apparent permeability coefficient (Papp) in the absence of their typical inhibitors to that in their presence.
Supplementary Figure 7 - Correlation between the relative protein expression levels of transporters and the ratio of the apparent permeability coefficient (Papp) in the absence of their typical inhibitors to that in their presence.
Supplementary Table 1 - Sequences of primers for mRNA quantification.
Supplementary Table 2 - Analytical conditions for quantification of test compounds with LC–MS/MS.
Supplementary Table 3 - MRM conditions for quantification of test compounds with LC–MS/MS.
Supplementary Table 4 - Reported values of IC50 or Ki of transporter inhibitors.
Supplementary Methods
Supplementary References
- Supplemental Data -